ArticleFrontiers in pharmacology2026
Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excessive hepatocyte apoptosis triggered by toxic bile acids is the core pathological event of cholestasis, and the direct target of luteolin (Lut), the major bioactive constituent of Methods: A murine cholestasis model was induced by α-naphthylisothiocyanate (ANIT), and the hepatocyte apoptotic pathways were validated in glycochenodeoxycholic acid (GCDCA)-treated HepG2 cells. Liver tissue pathological changes were assessed via hematoxylin-eosin (HE) histological staining. Network pharmacology paired with supplementary RNA sequencing (RNA-seq) was used to screen candidate pathways contributing to Lut's anti-cholestatic effects. Quantitative real-time PCR, Western blotting and Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) immunostaining were jointly utilized to assess apoptotic levels in liver parenchymal cells. Additionally, surface plasmon resonance (SPR) coupled with molecular docking simulations was adopted to clarify the direct binding profile of Lut. Results: Lut treatment markedly ameliorated serum biochemical indices and liver histopathological lesions in ANIT-exposed mice. Meanwhile, oxidative stress was alleviated, bile acid transporters were restored, inflammatory cytokines declined, and hepatocyte apoptosis was suppressed. Network pharmacology combined with RNA-seq predicted that Lut alleviates cholestasis through the Phosphatidylinositol 3-kinase/Protein Kinase B (PI3K/AKT)-mediated anti-apoptotic pathway. This hypothesis was further supported by TUNEL, Western blotting, and qRT-PCR analyses, which indicated that Lut could activate the PI3K/AKT, and then suppress hepatocyte apoptosis in cholestasis. SPR analysis revealed a concentration-dependent direct interaction between Lut and PI3K with a kinetic KD of 9.036 × 10 Conclusion: This study is the first to confirm that Lut directly targets PI3K to initiate the PI3K/AKT signaling cascade, and thereby suppresses bile acid-induced hepatocyte apoptosis. These findings refine the mechanistic understanding of Lut's hepatoprotective action from general antioxidant activity to target-specific anti-apoptotic signaling, and provide a molecular explanation for the traditional use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.